Search results

1. AbbVie has Met phase 3, again

   … tumours: CRC, GEA, NSCLC Teliso-A +/- Avastin Data at ASCO 2024 in CRC (>35% ORR in high cMet expressers at doses …

   
    

   Madeleine Armstrong
    
   - 02/25/2025 - 10:35

2. IMS 2024 – Darzalex fights back against Sarclisa

   … Venue International Myeloma Society 2024 ASCO 2024 mPFS NR vs 52.6 months with VRd NR vs … VRd=Velcade, Revlimid & dexamethasone. Source: IMS 2024 & ASCO 2024. Conferences Trial …

   
    

   Madeleine Armstrong
    
   - 10/01/2024 - 14:33

3. Akeso builds up its ivonescimab ambitions again

   … 2nd-line NSCLC Ivonescimab + chemo Chemo Data ASCO 2024: ORR 51% vs 35%, PFS 7.1 vs 4.8mo; OS 17.1 vs …

   
    

   Madeleine Armstrong
    
   - 09/26/2024 - 12:56

4. ESMO 2024 – combos could be the way forward for CDK2

   … Presentation ESMO 2024 ESMO 2024 ASCO 2023 ASCO 2024 Study Ph1 in solid tumours …

   
    

   Madeleine Armstrong
    
   - 09/15/2024 - 21:18

5. Replimune goes pivotal in uveal melanoma

   … R-, GM-CSF & anti-CTLA-4 Ph1 uveal melanoma data at ASCO 2024; ph2/3 begins Jan 2025 Note: …

   
    

   Madeleine Armstrong
    
   - 09/06/2024 - 15:47

6. Regeneron gets another bispecific blow

   … x CD28 Solid tumours (+ Libtayo) Ph1/2 data at ASCO 2024: 6% (3/51) ORR in MSS CRC; dose-expansion cohorts …

   
    

   Madeleine Armstrong
    
   - 08/23/2024 - 12:44

7. Tissue factor tempts Adcendo

   … DAR 3.8 Ph1/2 data in solid tumours presented at ASCO 2024 XNW28012 Evopoint Biosciences None …

   
    

   Madeleine Armstrong
    
   - 08/20/2024 - 14:15

8. Another vote of no-confidence in co-stimulated bispecifics

   … Ragistomig (ABL503) ABL Bio/ I-Mab Ph1 data at ASCO 2024 MCLA-145 Merus Ph1 Keytruda combo …

   
    

   Madeleine Armstrong
    
   - 08/07/2024 - 15:10

9. Boehringer takes on AbbVie in a novel checkpoint

   … Huadong Medicine PTPN2 inhibitor Preclinical data at ASCO 2024 Unnamed CD3 PTPN1/2 dual inhibitor …

   
    

   Madeleine Armstrong
    
   - 07/30/2024 - 15:58

10. Hookipa hopes for a head and neck fast track

    … 37% 53% CR rate 11% 18% Source: ASCO 2024. Data insights Trial …

    
     

    Madeleine Armstrong
     
    - 07/25/2024 - 13:39